NASDAQ
28.46USD
+0.36 (+1.28%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
266.8M
P/E
—
EPS
—
Beta
-6.18
52W range
18.85-29.43
Day range
27.95–28.99
Open
28.40
Prev close
28.10
Volume
135.3K
Avg volume
294.2K
Dividend
0.00
IPO
2026-04-17
https://www.globenewswire.com/news-release/2026/07/13/3325908/0/en/Alamar-Biosciences-Partners-with-Leading-Research-Universities-to-Launch-National-Initiative-Advancing-Blood-Based-Biomarkers-for-Neurodegenerative-Diseases.html · 7/13/2026+0.80
https://www.prnewswire.com/news-releases/precision-proteomics-leader-alamar-biosciences-lists-on-nasdaq-302746975.html · 4/20/2026+1.00
https://seekingalpha.com/article/4891871-alamar-biosciences-looking-for-early-detection · 4/19/2026+0.60
https://www.globenewswire.com/news-release/2026/04/17/3275924/0/en/Alamar-Biosciences-Announces-Pricing-of-Upsized-Initial-Public-Offering.html · 4/17/2026+0.80
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
